HHE Sponsored supplement: Sepsis | Page 12

Table 1 Summary of Toll-like receptors and ligands Receptor Ligands TLR1-2 Triacyl lipopeptides TLR2 Lipoteichoic acid, peptidoglycan, porins Phospholipomannan, B-glucans Viral hemagglutinin HMGB1 (high mobility group box) Viral double-stranded RNA TLR3 TLR4 Lipopolysaccharide, Manans (fungi), phospholipids (parasites), viral coat proteins, heat shock proteins, fibrinogen, HMGB1, hyaluronic acid, heparan sulfate Bacterial flagellin TLR5 Bacterial diacylated lipidopeptides, TLR2–6 lipoteichoic acid TLR7 Viral single-stranded RNA TLR8 Viral single-stranded RNA Unmethylated CpG (deoxy-cystidylate- TLR9 phosphate-deoxy-guanylate) Oligodeoxynucleotide DNA TLR10 Triacylated lipopeptides TLR11 Profilin Ligand origin Bacteria Bacteria (Gram-positive) Fungi Virus Host cells Virus Bacteria (Gram- negative) Fungi Parasites Host cells Bactera (Gram-positive and Gram-negative) Mycoplasma RNA viruses RNA viruses Bacteria DNA viruses Host cells Parasites Toxoplasma gondii TLR: Toll-like receptor of specific (mostly pro-inflammatory) genes (Table 2). These intracellular signalling cascades induce a series of antimicrobial mechanisms. 1,8 Tumour necrosis factor-alpha (TNFα) is one of the first cytokines released into the bloodstream after activation. In animal models, it produces symptoms very similar to septic shock and administration of anti-TNFα antibodies protects against death from sepsis. 9 TNFα binds through the receptors TNFR1 and 2 that are found in most cells. Binding induces the microbicidal activity of monocytes; increases production and migration of PMN; activates coagulation and complement; alters vascular tone and increased permeability; and increases protein catabolism and gluconeogenesis 10 among others, which give rise the typical symptoms seen in sepsis such as fever, diarrhoea, metabolic acidosis, neurotoxicity, cachexia and CID. 11 Interleukin-1 (IL-1a and IL-1b) act synergistically with TNF. IL-17 has also been implicated in the pathophysiology of sepsis. Antibody neutralisation of IL-17 in mouse models results in decreased organ damage and improved survival. 12 Micro-RNA also plays an important role in the inhibition of TLR/MyD88 feedback of signalling. 13 Phospholipase A2 activation in response to various inflammatory stimuli, including C5a, TNF-a, IL-1 or IL-6, generates arachidonic acid (AA) from membrane phospholipids. AA is metabolised via two pathways: the cycloxygenase (COX) pathway, which stimulates the synthesis of prostaglandins and thromboxanes; and the lipoxygenase (LO) pathway, responsible for the production of leukotrienes. COX and nitric oxide synthase are two of the main enzymes that mediate cardiovascular dysfunction and contribute, together with LO, to the progression to multiorgan failure in the septic patient. 14–16 NF-κB increases the expression of plasminogen activator inhibitor type 1 (PAI-1) and inhibits fibrinolysis, in addition to releasing cytokines that inhibit the expression of thrombomodulin, an important factor for the activation of protein C (inactivates pro-coagulant factors) and the decrease of the pro-coagulant activity of thrombin. 17,18 Iron metabolism is affected in sepsis both at the systemic and at the cellular level. Its ability to change oxidation states makes it an important cofactor in the transfer of electrons and oxidation reduction reactions in metabolic and signalling pathways. It is known that iron overload is associated with greater susceptibility to bacterial infections and high levels of ferritin have been linked to poor prognosis. 19,20 Altered cellular function of neutrophils, macrophages and monocytes are also associated with poor prognosis in patients with sepsis. Late neutrophil apoptosis and prolonged response of neutrophils are associated with increased organ damage, including acute respiratory distress syndrome, and reduced survival. 21 Both programmed cell death receptor 1 (PD-1) and adenosine receptors seem to play an important role. 22,23 Reactive oxygen species released by neutrophils are part of the positive feedback of the inflammatory response and cause both endothelial and mitochondrial dysfunction that contributes to the multi-organ failure. The decrease in the expression of the cell surface receptor HLA-DR in monocytes has been shown to be a predictor of nosocomial infection in patients with sepsis. 24 TH17 cells activate neutrophil responses and are increased in patients who survive sepsis. 25 Natural killer T cells are potent producers of IFNg and other pro-inflammatory cytokines and have cytotoxic effector functions. They promote the sepsis inflammatory response and are associated with increased mortality in elderly septic patients. 25 Mucosal-associated invariant T cells secrete IL-17 and IFNg after an infection. A decrease in the number of these cells correlates with the development of nosocomial infections. 26 Alteration of adaptive immunity in sepsis The adaptive immune system is characterised by its specificity and by having a memory Table 2 Genes transcribed after activation of NF-κB Types Genes transcribed Cytokines G-CSF, GM-CSF, TNFa, TNFb, IL-1a, IL-1b, IL-2, IL-3 IL-5 , IL-6, IL-12, IL-18 Chemokines MIP-1, MIP-2, GROa, GROb, GROg, RANTES TF, PAI-1 Coagulation factors Adhesion molecules E-selectin, P-selectin, VCAM-1, ICAM-1, ELAM, MadCam1 Immunoreceptors IL-2RA, MCH Acute phase proteins C reactive protein, LBP Enzymes iNOS, COX2, PLA2, LOX5, c3, MMP Costimulatory molecules B7.1 (CD80), B7.2 (CD86) G-CSF: granulocyte colony stimulating factor; GM-CSF: stimulating factor of granulocyte and monocyte-type colonies; TNF: tumour necrosis factor; IL: interleukin; MIP: macrophage inhibitor protein; GRO: growth-related oncogene; RANTES: normal T cell expressed and secreted; TF: tissue factor; PAI: plasminogen activator inhibitor; ELAM: endothelial cell leukocyte adhesion molecule-1; IL-2RA: receptor A of IL-2; MCH: major histocompatibility complex; LPB: LPS binding protein; iNOS: nitric oxide synthase; COX: cyclooxygenase; PLA: phospholipase A; LOX: lipoxygenase; C3: coagulation factor 3: MMP: matrix metalloproteinases. 12 HHE 2018 | hospitalhealthcare.com